BRIEF-AstraZeneca Says PT027 PhIII Asthma Trials Met Primary Endpoints

Sept 9 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - PT027 PHIII ASTHMA TRIALS MET PRIMARY ENDPOINTS

* ASTRAZENECA - FIXED-DOSE COMBINATION OF ALBUTEROL AND nft artists BUDESONIDE (PT027) DEMONSTRATED SIGNIFICANT BENEFITS FOR www.nftdrop.one ASTHMA PATIENTS IN MANDALA AND nft domain DENALI PHASE III TRIALS

* ASTRAZENECA - PT027 SIGNIFICANTLY REDUCED RISK OF SEVERE EXACERBATIONS COMPARED TO ALBUTEROL IN PATIENTS WITH MODERATE TO SEVERE ASTHMA

* ASTRAZENECA - PT027 SIGNIFICANTLY IMPROVED LUNG FUNCTION COMPARED TO INDIVIDUAL COMPONENTS IN MILD TO MODERATE ASTHMA IN DENALI TRIAL Source text for nft domain Eikon: nft domain Further company coverage:


adverts.addToArray("pos":"inread_player")Advertisement